ProPublica reports on Food and Drug Administration (FDA) involvement in approving DePuy’s metal-on-metal ASR hip implant for market.
Read the full story »
ProPublica reports on Food and Drug Administration (FDA) involvement in approving DePuy’s metal-on-metal ASR hip implant for market.
Consumer Reports profiles Dr. Stephen Tower, a 55-year-old orthopedic surgeon from Anchorage, Alaska, and an athlete who eagerly received his DePuy metal-on-metal hip in 2006. Dr. Tower tells Consumer Reports that he chose his DePuy …
In the latest news on hip implant recalls, the FDA announced today that it will hold a meeting in June 2012 to review mounting safety concerns about the failure rates of metal-on-metal hip replacements. Metal …
National Public Radio (NPR) follows Susy Mansfield, a DePuy metal-on-metal hip patient with a failed implant, on her journey to recovery through revision surgery. It is estimated that over half a million American patients have …
The Lancet, a leading British medical journal, published on March 13, 2012, a study of metal-on-metal hip implants which examines hip implant data from the National Joint Registry of England and Wales. The study concludes …
Britain’s Medicines and Healthcare products Regulatory Agency (MHRA) issued a press release on February 28, 2012, updating their advice on patient monitoring for metal-on-metal hip implants such as DePuy’s metal-on-metal ASR and Pinnacle hip implants. …
“Hundreds of thousands of patients around the world may have been exposed to toxic substances after being implanted with poorly regulated and potentially dangerous hip devices,” writes Deborah Cohen, an editor with the British Medical …
The New York Times reports that in August 2009, days after Johnson & Johnson received a letter from the FDA rejecting their metal-on-metal ASR Hip Resurfacing System for U.S. sales, company executive Pamela Plouhar emailed three other top executives to explain the FDA’s decision with statements that “contrast those made by the company in recent years about the all-metal hip.”
The New York Times reports, medical device manufacturer Johnson & Johnson continued to sell its ASR metal-on-metal hip implant devices abroad even after receivng a letter from the United States Food and Drug Administration (FDA) rejecting the hip implant’s sale in the U.S. The FDA rejected the hip implant device after reviewing Johnson & Johnson safety studies, and sent a nonapproval letter to the company in August 2009.
Johnson & Johnson has set aside $3 billion in special charges on its quarterly earnings statement to account for the costs of product liability litigation, Reuters reports. Johnson & Johnson’s subsidiary DePuy Orthopaedics recalled its …
Mass Device reports that the U.S. Food and Drug Administration (FDA) warned Johnson & Johnson’s subsidiary company DePuy Orthopaedics that several of its hip and knee implants were improperly marketed.
Lexi Hazam provides another update on the DePuy ASR hip implant recall litigation.
Wendy Fleishman explains why DePuy is liable for its failing ASR Hip Implants.
Lexi Hazam, provides an update on the DePuy ASR Hip.
Lexi Hazam discusses the DePuy recall & recent medical evidence on DePuy failure rates.
Lexi Hazam outlines steps to protect your privacy & legal rights if you are contacted by Broadspire. Lexi Hazam provides practical legal advice for patients undergoing revision surgery.
